The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database
- 19 October 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Diabetologica
- Vol. 50 (4), 569-577
- https://doi.org/10.1007/s00592-011-0340-7
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance databaseBritish Journal of Clinical Pharmacology, 2011
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based TherapiesGastroenterology, 2011
- Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event ReportingDiabetes Care, 2011
- Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBaseDiabetes Care, 2011
- Acute Pancreatitis in Association With Type 2 Diabetes and Antidiabetic DrugsDiabetes Care, 2010
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or SitagliptinDiabetes Care, 2010
- Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitisInternational Journal of Clinical Practice, 2010
- Antimicrobials and the Risk of Torsades de PointesDrug Safety, 2010
- Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 DiabetesDiabetes Care, 2009
- ???Extreme Duplication??? in the US FDA Adverse Events Reporting System DatabaseDrug Safety, 2007